Related references
Note: Only part of the references are listed.Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers
Ariane L. Herrick
CURRENT OPINION IN RHEUMATOLOGY (2016)
Raynaud's Phenomenon
Fredrick M. Wigley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
BSR and BHPR guideline for the treatment of systemic sclerosis
Christopher P. Denton et al.
RHEUMATOLOGY (2016)
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial
Hossein-Ardeschir Ghofrani et al.
LANCET RESPIRATORY MEDICINE (2016)
Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis
Michael Hughes et al.
RHEUMATOLOGY (2015)
Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review
Paloma Garcia de la Pena Lefebvre et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Raynaud's phenomenon: From molecular pathogenesis to therapy
Marcella Prete et al.
AUTOIMMUNITY REVIEWS (2014)
Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1)
Diana Bonderman et al.
CHEST (2014)
International consensus criteria for the diagnosis of Raynaud's phenomenon
Emanual Maverakis et al.
JOURNAL OF AUTOIMMUNITY (2014)
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vardenafil for the Treatment of Raynaud Phenomenon: A Randomized, Double-blind, Placebo-Controlled Crossover Study
Evren Caglayan et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1)
Hossein Ghofrani et al.
CHEST (2012)
Diagnosis and management of Raynaud's phenomenon
Beth Goundry et al.
BRITISH MEDICAL JOURNAL (2012)
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Johannes-Peter Stasch et al.
CIRCULATION (2011)
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension
F. Grimminger et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521:: An ascending-dose study in healthy male volunteers
Reiner Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The diagnosis and treatment of Raynaud's phenomenon - A practical approach
Janet E. Pope
DRUGS (2007)
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease
E Caglayan et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy
R Fries et al.
CIRCULATION (2005)
Raynaud's phenomenon.
FM Wigley
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes
C Desouza et al.
DIABETES CARE (2002)
Share Paper
